Overview

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

Status:
Not yet recruiting
Trial end date:
2025-05-08
Target enrollment:
Participant gender:
Summary
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen-Cilag Ltd.